Human Growth Hormone (HGH) vs Ipamorelin vs Tesamorelin
A three-way comparison to help you find the right peptide for your research goals.
Human Growth Hormone (HGH)
Human Growth Hormone (somatropin) is a 191-amino acid protein identical to naturally produced GH. FDA-approved for growth hormone deficiency, Turner syndrome, and other conditions. Widely used off-label for anti-aging and performance.
Full details →Ipamorelin
Ipamorelin is a selective growth hormone secretagogue that stimulates the release of growth hormone from the pituitary gland without significantly affecting cortisol or prolactin.
Full details →Tesamorelin
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.
Full details →Side-by-Side Comparison
| Aspect | Human Growth Hormone (HGH) | Ipamorelin | Tesamorelin |
|---|---|---|---|
| Dose Range | 200 mcg–2 mg | 100 mcg–300 mcg | 2 mg |
| Frequency | 1x daily | 2x daily | 1x daily |
| Cycle Length | 12–24 weeks | 8–12 weeks | 8–52 weeks |
| Route | subcutaneous | subcutaneous | subcutaneous |
| Mechanism | Binds to GH receptors throughout the body, stimulating IGF-1 production in the liver. Promotes protein synthesis, fat metabolism, and cellular regeneration across multiple tissues. | Acts as a ghrelin mimetic, binding to the ghrelin receptor (GHS-R) in the pituitary to stimulate GH release. Highly selective with minimal effect on other hormones. | Stimulates the pituitary gland to produce and release growth hormone by binding to GHRH receptors. Increases IGF-1 levels which promotes lipolysis and reduces visceral adipose tissue. |
| Typical Dosage | Medical: 0.1-0.3mg/kg/week divided into daily doses. Anti-aging: 1-2 IU daily. Performance: 2-6 IU daily, sometimes higher. | Typical dosing ranges from 200-300mcg administered 2-3 times daily, often combined with CJC-1295. | FDA-approved dose: 2mg administered subcutaneously once daily. Research protocols may use various dosing schedules. |
| Administration | Subcutaneous injection, preferably at night to mimic natural pulsatile release. Rotate injection sites. Store refrigerated. | Subcutaneous injection. Best results when administered fasted or before sleep. Often stacked with GHRH peptides. | Subcutaneous injection into the abdomen. Rotate injection sites. Best administered at the same time daily, preferably in the evening. |
| Side Effects | Joint pain, water retention, carpal tunnel syndrome, potential insulin resistance, and acromegaly features with long-term high doses. | Generally well-tolerated. May cause mild headaches, lightheadedness, or increased hunger initially. | Common side effects include injection site reactions (erythema, pruritus), joint pain, peripheral edema, and muscle pain. May cause elevated blood glucose. |
| Best For |
What They Have in Common
Human Growth Hormone (HGH), Ipamorelin, Tesamorelin are all commonly used for:
Key Differences
Unique to Human Growth Hormone (HGH):
Unique to Ipamorelin:
Which Has Stronger Evidence?
| Goal | Human Growth Hormone (HGH) | Ipamorelin | Tesamorelin |
|---|---|---|---|
| Muscle Growth | high | high | medium |
| Fat Loss | high | high | high |
Key Studies
Human Growth Hormone (HGH)
- Transgenic Artifacts Caused by Passenger Human Growth Hormone.
Trends in endocrinology and metabolism: TEM, 2018
- [Human growth hormone and Turner syndrome].
Anales de pediatria (Barcelona, Spain : 2003), 2017
- Significance of the disulphide bonds of human growth hormone.
Endokrynologia Polska, 2013
Ipamorelin
- The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus.
Animal reproduction science, 2024
- The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism.
Physiology & behavior, 2024
- Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.
International journal of colorectal disease, 2014
Tesamorelin
- Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol.
BMJ open, 2026
- Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.
The Journal of infectious diseases, 2025
- Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.
AIDS (London, England), 2024
Ready to Learn More?
Looking for trusted sources?